Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

• Egile Nagusiak: Agnieszka Karbownik (Egilea), Danuta Szkutnik-Fiedler (Egilea), Andrzej Czyrski (Egilea), Natalia Kostewicz (Egilea), Paulina Kaczmarska (Egilea), Małgorzata Bekier (Egilea), Joanna Stanisławiak-Rudowicz (Egilea), Marta Karaźniewicz-Łada (Egilea), Anna Wolc (Egilea), Franciszek Główka (Egilea), Edmund Grześkowiak (Egilea), Edyta Szałek (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2020-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and multidrug and toxin extrusion (MATE) are involved in...